Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free TMO Stock Alerts

Thermo Fisher Scientific (TMO) Competitors

Thermo Fisher Scientific logo
$457.08 -7.92 (-1.70%)
As of 01:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

TMO vs. MEDP, A, AMN, BIO, and BIO.B

Should you be buying Thermo Fisher Scientific stock or one of its competitors? The main competitors of Thermo Fisher Scientific include Medpace (MEDP), Agilent Technologies (A), AMN Healthcare Services (AMN), Bio-Rad Laboratories (BIO), and Bio-Rad Laboratories (BIO.B). These companies are all part of the "medical" sector.

How does Thermo Fisher Scientific compare to Medpace?

Thermo Fisher Scientific (NYSE:TMO) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Thermo Fisher Scientific has higher revenue and earnings than Medpace. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B3.81$6.70B$18.1925.13
Medpace$2.68B4.48$451.12M$15.9126.42

Thermo Fisher Scientific has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

In the previous week, Thermo Fisher Scientific had 12 more articles in the media than Medpace. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 30 mentions for Medpace. Thermo Fisher Scientific's average media sentiment score of 1.05 beat Medpace's score of 0.19 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
28 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Medpace
5 Very Positive mention(s)
0 Positive mention(s)
25 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Thermo Fisher Scientific presently has a consensus price target of $619.65, indicating a potential upside of 35.57%. Medpace has a consensus price target of $467.08, indicating a potential upside of 11.13%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
3.00
Medpace
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20

Medpace has a net margin of 17.19% compared to Thermo Fisher Scientific's net margin of 15.15%. Medpace's return on equity of 120.89% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.15% 16.86% 8.15%
Medpace 17.19%120.89%24.79%

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats Medpace on 10 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Agilent Technologies has a net margin of 18.26% compared to Thermo Fisher Scientific's net margin of 15.15%. Agilent Technologies' return on equity of 24.49% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Agilent Technologies18.26% 24.49% 12.83%
Thermo Fisher Scientific 15.15%16.86%8.15%

Agilent Technologies presently has a consensus price target of $163.71, indicating a potential upside of 45.23%. Thermo Fisher Scientific has a consensus price target of $619.65, indicating a potential upside of 35.57%. Given Agilent Technologies' higher possible upside, equities research analysts clearly believe Agilent Technologies is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilent Technologies
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00
Thermo Fisher Scientific
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
3.00

Thermo Fisher Scientific has higher revenue and earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$6.95B4.58$1.30B$4.5324.88
Thermo Fisher Scientific$44.56B3.81$6.70B$18.1925.13

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.9%. Thermo Fisher Scientific pays an annual dividend of $1.88 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 22.5% of its earnings in the form of a dividend. Thermo Fisher Scientific pays out 10.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has increased its dividend for 9 consecutive years and Thermo Fisher Scientific has increased its dividend for 8 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Agilent Technologies has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

In the previous week, Thermo Fisher Scientific had 33 more articles in the media than Agilent Technologies. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 9 mentions for Agilent Technologies. Thermo Fisher Scientific's average media sentiment score of 1.05 beat Agilent Technologies' score of 0.97 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agilent Technologies
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
28 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Thermo Fisher Scientific beats Agilent Technologies on 10 of the 18 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Thermo Fisher Scientific has a net margin of 15.15% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services-0.95% 18.01% 5.19%
Thermo Fisher Scientific 15.15%16.86%8.15%

AMN Healthcare Services presently has a consensus price target of $23.50, indicating a potential downside of 22.42%. Thermo Fisher Scientific has a consensus price target of $619.65, indicating a potential upside of 35.57%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
2 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.44
Thermo Fisher Scientific
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
3.00

Thermo Fisher Scientific has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.73B0.43-$95.70M-$0.87N/A
Thermo Fisher Scientific$44.56B3.81$6.70B$18.1925.13

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AMN Healthcare Services has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.

In the previous week, Thermo Fisher Scientific had 27 more articles in the media than AMN Healthcare Services. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 15 mentions for AMN Healthcare Services. Thermo Fisher Scientific's average media sentiment score of 1.05 beat AMN Healthcare Services' score of 0.65 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
28 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Thermo Fisher Scientific beats AMN Healthcare Services on 14 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, Thermo Fisher Scientific had 38 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 4 mentions for Bio-Rad Laboratories. Thermo Fisher Scientific's average media sentiment score of 1.05 beat Bio-Rad Laboratories' score of 0.97 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
28 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Thermo Fisher Scientific has a net margin of 15.15% compared to Bio-Rad Laboratories' net margin of 6.52%. Thermo Fisher Scientific's return on equity of 16.86% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Thermo Fisher Scientific 15.15%16.86%8.15%

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B2.56$759.90M$6.0740.72
Thermo Fisher Scientific$44.56B3.81$6.70B$18.1925.13

Bio-Rad Laboratories presently has a consensus price target of $333.00, indicating a potential upside of 34.71%. Thermo Fisher Scientific has a consensus price target of $619.65, indicating a potential upside of 35.57%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Thermo Fisher Scientific
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
3.00

Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, Thermo Fisher Scientific had 38 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 42 mentions for Thermo Fisher Scientific and 4 mentions for Bio-Rad Laboratories. Thermo Fisher Scientific's average media sentiment score of 1.05 beat Bio-Rad Laboratories' score of 0.56 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
28 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Thermo Fisher Scientific has a net margin of 15.15% compared to Bio-Rad Laboratories' net margin of 6.52%. Thermo Fisher Scientific's return on equity of 16.86% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Thermo Fisher Scientific 15.15%16.86%8.15%

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B2.65$759.90M$6.0742.10
Thermo Fisher Scientific$44.56B3.81$6.70B$18.1925.13

Thermo Fisher Scientific has a consensus price target of $619.65, indicating a potential upside of 35.57%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Thermo Fisher Scientific
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
3.00

Bio-Rad Laboratories has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.

Get Thermo Fisher Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMO vs. The Competition

Export
MetricThermo Fisher ScientificMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$169.86B$6.73B$6.20B$22.92B
Dividend Yield0.40%1.72%2.78%4.02%
P/E Ratio25.1348.7520.6829.00
Price / Sales3.8136.01558.0324.48
Price / Cash15.3025.2027.8119.21
Price / Book3.226.529.824.66
Net Income$6.70B$158.34M$3.55B$1.07B
7 Day PerformanceN/AN/AN/A-0.89%
1 Month Performance-7.91%3.90%6.72%4.15%
1 Year Performance13.44%-0.52%42.70%29.23%

Thermo Fisher Scientific Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMO
Thermo Fisher Scientific
4.7623 of 5 stars		$457.08
-1.7%		$619.65
+35.6%		+15.3%$169.86B$44.56B25.13125,000
MEDP
Medpace
2.8487 of 5 stars		$417.02
-0.1%		$467.08
+12.0%		+43.2%$11.91B$2.53B26.216,200
A
Agilent Technologies
4.9596 of 5 stars		$112.15
-2.1%		$163.71
+46.0%		+8.0%$31.69B$6.95B24.7618,100
AMN
AMN Healthcare Services
1.4509 of 5 stars		$20.76
-1.7%		$22.64
+9.0%		+31.2%$802.34M$2.73BN/A2,664
BIO
Bio-Rad Laboratories
3 of 5 stars		$257.80
+0.5%		$333.00
+29.2%		+6.5%$6.96B$2.59B42.477,450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:TMO) was last updated on 5/11/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel